Intravesical Therapies in Non-muscle Invasive Bladder Tumors
Journal Title: Üroonkoloji Bülteni - Year 2019, Vol 18, Issue 1
Abstract
In the European Association of Urology (EAU) 2015 Guidelines for non-muscle invasive bladder tumors, maintenance Bacillus Calmette-Guérin (BCG) therapy is a grade A recommendation. In the intermediate-risk group, re-evaluation is recommended after 1-year full-dose treatment; in the highrisk group, full-dose BCG is recommended for 1-3 years. Intravesical BCG therapy fails in 40% patients in an average of 2 years. In these cases, there is no alternative treatment that is considered effective. In patients with failed BCG, comparison of BCG and gemcitabine showed less recurrence in the long term with gemcitabine while progression and toxicity were similar. Early radical cystectomy should be considered in non-muscle invasive bladder cancer patients with BCG-refractory T1G3 who have good performance status and low comorbidity. In T1 tumors, invade deeper than 3 mm and/or larger than 6 mm in diameter has been associated with a 100% progression rate. BCG decreased recurrence more significantly in high-risk Ta and T1 tumors. In terms of progression of high-risk superficial bladder cancer, comparison of mitomycin C and BCG showed that BCG is superior if maintenance therapy is given. EAU guidelines recommend early bladder chemotherapy instillation (EBCI), in the low-to-intermediate risk group. There was no clear effect of EBCI in the intermediate- and high-risk group. EBCI alone reduces recurrence only in the low-risk group. However, adjuvant intravesical chemotherapy (AIVC) is recommended in the intermediate- and high-risk groups because it improves relapse-free survival. BCG and maintenance BCG therapy were found to be more effective than AIVC in reducing progression and preventing recurrence.
Authors and Affiliations
Serdar Geyik
Keywords
Related Articles
- EP ID EP550869
- DOI 10.4274/uob.galenos.2018.1116
- Views 98
- Downloads 0
The Efficiency of Docetaxel Chemotherapy on Castration Resistant Prostate Cancer: Singe Center Experience
Objective: Prostate cancer (PCa) is the second most commonly seen cancer type worldwide. Mortality due to PCa is mostly linked to the development of castration resistant PCa (CRPC). In these patients, the main treatment...
Association between Hormonal Evaluation Before Prostate Needle Biopsy and Locally Advanced Prostate Cancer
Objective: In this study, patients hormonally evaluated before prostate needle biopsy were considered among the ones who underwent radical prostatectomy (RRP) due to prostate adenocarcinoma and had locally advanced patho...
Do the Pain Scores During Transrectal Ultrasound-guided Prostate Rebiopsy Change in Patients with a Prior History of Prostate Biopsy?
Objective: In this study we evaluated the effects of prior history of prostate biopsy on pain scores of patients who underwent transrectal ultrasound-guided prostate biopsy (TRUS-PBx). Materials and Methods: Between Octo...
Immunotherapy in Prostate Cancer
In recent years, immunotherapy has become an important treatment alternative in the treatment of many cancers. Research on immunotherapy in prostate cancer has been accelerated by obtaining Food and Drug Administration (...
Magnetic Resonance - Transrectal Ultrasound Fusion Guided Prostate Biopsy
Prostate has remained as the single solid organ for which biopsy cannot be performed from a lesion for decades. Lately, the groundbreaking magnetic resonance imaging (MRI) techniques have emerged to scan prostate cancer...